Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting

Cancer Immunology, Immunotherapy

Volumn 59, Issue 5, 2010, Pages 687-695

  May, M ^a   Brookman May, Sabine ^a   Hoschke, Bernd ^b   Gilfrich, Christian ^a   Kendel, Friederike ^c   Baxmann, Susann ^d   Wittke, Stefan ^d   Kiessig, Stephan T ^d   Miller, Kurt ^c   Johannsen, Manfred ^c  

^a Urologische Klinik   (Germany)

^b Carl Thiem Hospital Cottbus   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Haema AG   (Germany)

Author keywords

Adjuvant treatment; Autologous tumour vaccine; Nephrectomy; Overall survival; Renal cell carcinoma

Indexed keywords

ALPHA TOCOPHEROL; CANCER VACCINE; RECOMBINANT GAMMA INTERFERON; RENIALE; TUMOR LYSATE VACCINE; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; ADOLESCENT; CLINICAL TRIAL; COMPASSIONATE USE; KAPLAN MEIER METHOD; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; COMPASSIONATE USE TRIALS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; YOUNG ADULT;

EID: 77950503440     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0784-6     Document Type: Article

References (22)

1. Asemissen AM, Brossart P (2009) Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother 58(7): 1169-1174
2. Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, de La Taille A, Altieri V, Lobel B, Zigeuner RE, Artibani W, Guillé F, Abbou CC, Salzano L, Gallo C (2005) Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104(7): 1362-1371 (Pubitemid 41356151)
3. Doehn C, Esser N, Pauels HG, Kießig ST, Stelljes M, Grossmann A, Jocham D, Drevs J (2008) Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Eur Urol Jun 4 [Epub ahead of print]
4. Doehn C, Merseburger AS, Jocham D, Kuczyk MA (2007) Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer? Urologe A 46(10):1371-1372, 1374, 1376-1378 (German)
5. Doehn C (2006) Prolongation of progression-free and overall survival following an adjuvant vaccination with Reniale in patients with non-metastatic renal cell carcinoma: secondary analysis of a multicenter phase-3 trial. Abstract presented at Deutscher Krebskongress, 22-26 March 2006, Berlin, Germany
6. Ficarra V, Galfano A, Guillé F, Schips L, Tostain J, Mejean A, Lang H, Mulders P, De La Taille A, Chautard D, Descotes JL, Cindolo L, Novara G, Rioux-Leclercq N, Zattoni F, Artibani W, Patard JJ (2007) A new staging system for locally advanced (pT34) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol 178(2):418-424 (Pubitemid 47030485)
7. Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C, Talamini R (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumour cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. Cancer 77(12):2560-2566 (Pubitemid 26169153)
8. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim. J, Doehn C (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renalcell carcinoma after radical nephrectomy phase III randomised controlled trial. Lancet 363(9409):594-599 (Pubitemid 38264176)
9. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25(11): 1316-1322 (Pubitemid 46706877)
10. May M, Kendel F, Hoschke B, Gilfrich C, Kiessig S, Pflanz S, Seidel M, Brookman-Amissah S (2009) Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years. Urologe A 48(9): 1075-1083
11. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D, Eastern Cooperative Oncology Group/Intergroup trial (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21(7):1214-1222
12. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in. metastatic renal-cell carcinoma. N Engl J Med 356(2): 115-124 (Pubitemid 46089672)
13. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19(2):425-431 (Pubitemid 32112855)
14. Repmann R, Goldschmidt AJ, Richter A (2003) Adjuvant therapy of renal cell carcinoma patients with an autologous tumour cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res 23(2A):969-974 (Pubitemid 36750904)
15. Repmann R, Wagner S, Richter A ( 1997) Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumour vaccine. Anticancer Res 17(4B):2879-2882 (Pubitemid 27434810)
16. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669): 1119-1132
17. Rosenbaum PR, Rubin DB (1985) The bias due to incomplete matching. Biometrics 41(1):103-116
18. Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED, Southwest Oncology Group (2007) Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25(22):3296-3301 (Pubitemid 47325615)
19. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173(1):48-51 (Pubitemid 39627669)
20. Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML, Frank I (2007) Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 177(2):477-480 (Pubitemid 46054015)
21. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 272:145-154
22. Wood C, Srivastava P, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Teofilovici F, Isakov L, Escudier B (2009). Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. ASCO no. 3009